

CLAIMS:

1. An antibody that binds human CD19, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein
 - the HCDR1 comprises SEQ ID NO: 29,
 - the HCDR2 comprises SEQ ID NO: 30,
 - the HCDR3 comprises SEQ ID NO: 31,
 - the LCDR1 comprises SEQ ID NO: 32,
 - the LCDR2 comprises SEQ ID NO: 33, and
 - the LCDR3 comprises SEQ ID NO: 34.
2. The antibody of claim 1, wherein the VH comprises SEQ ID NO: 37 and the VL comprises SEQ ID NO: 41.
3. The antibody of claim 1 or 2, wherein the antibody comprises a heavy chain (HC) comprising SEQ ID NO: 35 and a light chain (LC) comprising SEQ ID NO: 39.
4. The antibody of claim 1 or 2, wherein the antibody comprises a HC comprising SEQ ID NO: 52 and a LC comprising SEQ ID NO: 39.
5. An antibody that binds human CD19, wherein the antibody comprises a VH and a VL, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the VL comprises LCDR1, LCDR2, and LCDR3, wherein
 - the HCDR1 comprises SEQ ID NO: 29,
 - the HCDR2 comprises SEQ ID NO: 30,
 - the HCDR3 comprises SEQ ID NO: 31,
 - the LCDR1 comprises SEQ ID NO: 43,
 - the LCDR2 comprises SEQ ID NO: 44, and
 - the LCDR3 comprises SEQ ID NO: 45.

6. The antibody of claim 5, wherein the VH comprises SEQ ID NO: 37 and the VL comprises SEQ ID NO: 48.
7. The antibody of claim 5 or 6, wherein the antibody comprises a HC comprising SEQ ID NO: 35 and a LC comprising SEQ ID NO: 46.
8. The antibody of claim 5 or 6, wherein the antibody comprises a HC comprising SEQ ID NO: 52 and a LC comprising SEQ ID NO: 46.
9. An antibody that binds human CD19, wherein the antibody comprises a VH and a VL, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the VL comprises LCDR1, LCDR2, and LCDR3, wherein
 - the HCDR1 comprises SEQ ID NO: 15,
 - the HCDR2 comprises SEQ ID NO: 16,
 - the HCDR3 comprises SEQ ID NO: 17,
 - the LCDR1 comprises SEQ ID NO: 18,
 - the LCDR2 comprises SEQ ID NO: 19, and
 - the LCDR3 comprises SEQ ID NO: 20.
10. The antibody of claim 9, wherein the VH comprises SEQ ID NO: 23 and the VL comprises SEQ ID NO: 27.
11. The antibody of claim 9 or 10, wherein the antibody comprises a HC comprising SEQ ID NO: 21 and a LC comprising SEQ ID NO: 25.
12. The antibody of claim 9 or 10, wherein the antibody comprises a HC comprising SEQ ID NO: 54 and a LC comprising SEQ ID NO: 25.
13. The antibody of any one of claims 1-12, wherein the antibody is a non-depleting antibody.

14. A nucleic acid comprising a sequence encoding SEQ ID NO: 35, 52, 39, 46, 21, 54, or 25.
15. A vector comprising the nucleic acid of claim 14.
16. The vector of claim 15, wherein the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second nucleic acid sequence encoding SEQ ID NO: 39 or 46.
17. The vector of claim 15, wherein the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 21 or 54, and a second nucleic acid sequence encoding SEQ ID NO: 25.
18. A composition comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 39 or 46.
19. A composition comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 21 or 54, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 25.
20. A cell comprising the vector of claim 16 or 17.
21. A cell comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 39 or 46.
22. A cell comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 21 or 54, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 25.
23. The cell of any one of claims 20-22, wherein the cell is a mammalian cell.

24. A process of producing an antibody comprising culturing the cell of any one of claims 20-23 under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.
25. An antibody produced by the process of claim 24.
26. A pharmaceutical composition comprising the antibody of any one of claims 1-13 or 25, and a pharmaceutically acceptable excipient, diluent or carrier.
27. A method of treating a B cell associated disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of any one of claims 1-13 or 25, or the pharmaceutical composition of claim 26.
28. The method of claim 27, wherein the B cell associated disorder is an autoimmune disease.
29. The method of claim 27, wherein the B cell associated disorder is selected from systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome, idiopathic thrombocytopenia purpura, Type 1 diabetes, pemphigus vulgaris, neuromyelitis optica, ANCA vasculitis, or myasthenia gravis.
30. The antibody of any one of claims 1-13 or 25 for use in therapy.
31. The antibody of any one of claims 1-13 or 25, or the pharmaceutical composition of claim 26, for use in the treatment of a B cell associated disorder.
32. The antibody or pharmaceutical composition of claim 31, wherein the B cell associated disorder is an autoimmune disease.
33. The antibody or pharmaceutical composition of claim 31, wherein the B cell associated disorder is selected from systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis,

Sjogren's syndrome, idiopathic thrombocytopenia purpura, Type 1 diabetes, pemphigus vulgaris, neuromyelitis optica, ANCA vasculitis, or myasthenia gravis.

34. Use of the antibody of any one of claims 1-13 or 25, in the manufacture of a medicament for the treatment of a B cell associated disorder.

35. The use of claim 34, wherein the B cell associated disorder is an autoimmune disease.

36. The use of claim 34, wherein the B cell associated disorder is selected from systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome, idiopathic thrombocytopenia purpura, Type 1 diabetes, pemphigus vulgaris, neuromyelitis optica, ANCA vasculitis, or myasthenia gravis.